Research programme: dopamine D3 receptor antagonists - sanofi-aventis
Alternative Names: MDL 815541; MDL 815994Latest Information Update: 17 Mar 2009
At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Anxiety disorders; Migraine; Schizophrenia; Substance-related disorders
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
- 10 Apr 2003 Preclinical trials in Alzheimer's disease (unspecified route)
- 10 Apr 2003 Preclinical trials in Migraine (unspecified route)